CheckMate 744 R2 cohort study design and patient disposition. Response rates are reported before consolidation. Patients who achieved partial metabolic response (PMR)/no metabolic response (NMR) per blinded independent central review (BICR) after 4 cycles of nivolumab plus BV induction received intensification with BV plus bendamustine. Patients who achieved CMR per BICR after 4 cycles of nivolumab plus BV induction or after 2 or 4 cycles of BV plus bendamustine intensification proceeded to consolidation with high-dose chemotherapy (HDCT) and auto-HCT. Patients who had progressive metabolic disease (PMD) after induction, or PMR, NMR, or PMD after intensification, could proceed to follow-up. Shaded area indicates study treatment phases. ^aPET–computed tomography/magnetic resonance imaging (real-time BICR) was performed after 4 cycles of nivolumab plus BV and after every 2 cycles of BV plus bendamustine before consolidation. ^bIf approved by study medical monitor. ^cOne patient received ifosfamide, carboplatin, and etoposide for progression. ^dPatients who withdrew consent during the study or who proceeded to follow-up after induction were included for response assessment.